OAZ2: A Potential Drug Target (G4947)

Target Name: OAZ2

NCBI ID: G4947

OAZ2

OAZ2: A Potential Drug Target

OAZ2 (ODC-Az 2) is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, kidneys, and liver. It is a member of the Azure family of proteins, which are involved in a variety of cellular processes, including cell signaling, DNA replication, and stress response.

One of the unique features of OAZ2 is its ability to interact with the protein p21, also known as the tumor suppressor protein TSP50. p21 is a transmembrane protein that is involved in the regulation of cell growth, apoptosis, and adhesion. It has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Azure proteins, including OAZ2, have been identified as potential drug targets due to their involvement in various cellular processes that are disrupted in diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. OAZ2 has also been shown to play a role in the development and progression of certain diseases, which further increases its potential as a drug target.

In addition to its involvement in cellular processes, OAZ2 has also been shown to play a role in the regulation of inflammation. It has been shown to interact with various cytokines, including TNF-alpha, IL-1, and IL-6. This suggests that OAZ2 may be involved in the regulation of inflammatory responses and may be a potential target for drugs that are designed to alleviate inflammation.

Furthermore, OAZ2 has also been shown to play a role in the regulation of cell signaling. It has been shown to interact with various transcription factors, including NF-kappa-B and SMARTCO. This suggests that OAZ2 may be involved in the regulation of cellular signaling pathways and may be a potential target for drugs that are designed to alter cellular signaling.

In conclusion, OAZ2 is a protein that has been identified as a potential drug target due to its involvement in various cellular processes that are disrupted in diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. Its ability to interact with the tumor suppressor protein p21 and its involvement in the regulation of inflammation and cell signaling make it an attractive candidate for further research and development as a potential drug.

Protein Name: Ornithine Decarboxylase Antizyme 2

Functions: Ornithine decarboxylase (ODC) antizyme protein that negatively regulates ODC activity and intracellular polyamine biosynthesis and uptake in response to increased intracellular polyamine levels. Binds to ODC monomers, inhibiting the assembly of the functional ODC homodimers. Does not target the ODC monomers for degradation, which allows a protein synthesis-independent restoration of ODC activity (PubMed:17900240). Involved in the translocation of AZIN2 from ER-Golgi intermediate compartment (ERGIC) to the cytosol (By similarity)

The "OAZ2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OAZ2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets